drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor (CAR) T-cell therapy engineered from a patient’s T cells to express a CAR targeting LGR5, leading to antigen-dependent T-cell activation and cytotoxic killing of LGR5-positive tumor cells; administered as a single IV infusion after lymphodepleting chemotherapy with dose levels ranging from 2.5×10^7 to 1.5×10^9 cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor specific for LGR5; CAR engagement of LGR5 on tumor cells triggers antigen-dependent T-cell activation and cytotoxic killing of LGR5-positive cancer cells.
drug_name
CNA3103
nct_id_drug_ref
NCT05759728